Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 3/20 | 0.50 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | PDE6D | O43924 | 1/20 | 0.49 |
| ▸ | PDE8A | O60658 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | PDE9A | O76083 | 1/20 | 0.49 |
| ▸ | PDE8B | O95263 | 1/20 | 0.49 |
| ▸ | PDE6A | P16499 | 1/20 | 0.49 |
| ▸ | PDE6G | P18545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4784667 | 0.92 | PARP1 (0.49) | PARP1AURKAKDM4EGRIN2DGRIN3B | |
| SCHEMBL340944 | 0.83 | PRKD3 (0.49) | PARP1AURKAKDM4EDAOATAD2 | |
| SCHEMBL29480586 | 0.83 | PRKD3 (0.49) | PARP1AURKAKDM4EDAOATAD2 | |
| Hydrochloric Acid SCHEMBL30775701 | 0.81 | PRKD3 (0.47) | PARP1AURKAKDM4EDAOATAD2 | |
| Hydrochloric Acid SCHEMBL30594385 | 0.81 | PRKD3 (0.47) | PARP1AURKAKDM4EDAOATAD2 | |
| SCHEMBL2121736 | 0.76 | PRKD3 (0.44) | PARP1AURKAKDM4EDAOATAD2 | |
| SCHEMBL14890226 | 0.76 | PARP1 (0.46) | PARP1AURKAKDM4EDAOATAD2 | |
| Biphenyl SCHEMBL28782742 | 0.75 | GSK3A (0.63) | PARP1AURKAKDM4EPDE2APDE3B | |
| SCHEMBL259028 | 0.74 | MAPT (0.52) | PARP1AURKAKDM4E | |
| SCHEMBL29967265 | 0.74 | MAPT (0.52) | PARP1AURKAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | claimed |
| WO-2022072783-A1 | BICYCLIC DIONE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2022-04-07 | — | — | WO | claimed |
| CN-119192357-A | Antibodies and methods for treating influenza a infection | 胡默波斯生物医学公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-115803328-B | Piperazine-2, 3-dione derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023229378-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023229380-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| US-11633415-B2 | Compounds and methods useful for treating or preventing cancers | THE BROAD INSTITUTE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| CN-115803328-A | Piperazine-2, 3-dione derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022114812-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2022-06-02 | — | — | WO | disclosed |
| EP-3504208-A1 | TRIAZOLOPYRAZINONE DERIVATIVE USEFUL AS A HUMAN PDE1 INHIBITOR | Eli Lilly and Company (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018183936-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | ZENTARIS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| US-5863916-A | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER-EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1999-01-26 | — | — | US | disclosed |
| US-5620978-A | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0743855-A1 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARMACEUTICALS, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995018616-A2 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARM INC (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149484-A1 | NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES | MAP4K2, MAP3K15, MAP3K5 | PARP1 840/4885AURKA 284/4885KDM4E 1430/4885 |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | PARP1 772/4885AURKA 1976/4885KDM4E 3922/4885 |
| US-11633415-B2 | Compounds and methods useful for treating or preventing cancers | CSNK1A1, CSNK2A1, CSNK2A3 | PARP1 179/4885AURKA 362/4885KDM4E 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.